936092-48-7

Basic information

• Product Name: 2-chloro-5-methyl-N⁴-(3-methoxyphenyl)pyrimidin-4-amine
• Synonyms: 2-chloro-5-methyl-N⁴-(3-methoxyphenyl)pyrimidin-4-amine
• CAS NO: 936092-48-7
• Molecular Weight: 249.7
• Mol File: 936092-48-7.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: 2-chloro-5-methyl-N⁴-(3-methoxyphenyl)pyrimidin-4-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-5-methyl-N⁴-(3-methoxyphenyl)pyrimidin-4-amine(936092-48-7)
• EPA Substance Registry System: 2-chloro-5-methyl-N⁴-(3-methoxyphenyl)pyrimidin-4-amine(936092-48-7)

Safety Data

• Hazardous Substances Data: 936092-48-7(Hazardous Substances Data)

Upstream product

• 2398-37-0 3-methoxyphenyl bromide 
• 14394-70-8 2-chloro-4-amino-5-methylpyrimidine 
• 1780-31-0 2,6-dichloro-5-methylpyrimidine 
• 536-90-3 m-Anisidine 

Relevant articles and documents

Synthesis and biological evaluation of novel 2,4-dianilinopyrimidine derivatives as potent dual janus kinase 2 and histone deacetylases inhibitors

Dual or multiple-targeting inhibition of oncogenic targets in a single molecule could be an alternative approach to drug combinations. Previous studies have revealed that histone deacetylases (HDAC) inhibitor in combination with janus kinase (JAK) inhibitor could exhibit synergistically anti-proliferative effects in cancer treatment. Herein, we presented a novel series of 2,4-dianilinopyrimidine derivatives, which could simultaneously inhibit JAK2 and HDAC1. Among which, 7l was found to be the most potent compound and displayed balanced inhibitory activity against HDAC1 (IC50 = 1.9 nM) and JAK2 (IC50 = 0.5 nM), respectively. 7l also demonstrated good antiproliferative activity against tested cancer cell lines (A549, HepG-2, MDA-MB-231 and Jurkat). Moreover, flow cytometric analysis showed that 7l induced apoptosis and cell cycle arrest in a dose-dependent manner, and the insight into mechanisms of 7l indicated that it could decrease the phosphorylation of STAT-3 and promote histone acetylation. In conclusion, these results together suggested that 7l would be a promising lead candidate and deserved further research and development.

POTENT DUAL BRD4-KINASE INHIBITORS AS CANCER THERAPEUTICS

Disclosed herein are compounds that are inhibitors of BRD4 and their use in the treatment of cancer. Methods of screening for selective inhibitors of BRD4 are also disclosed. In certain aspects, disclosed are compounds of Formula I-IV.